

TAGLICH BROTHERS

MEMBER: FINRA, SIPC | WWW.TAGLICHBROTHERS.COM

Final Report

Investors should consider this report as only a single factor in making their investment decision.

Cosmos Health Inc.

Discontinued

Howard Halpern

March 3, 2025

COSM \$0.54 — (NASDAQ)

	2022 A	2023 A	9M24 A
Total Revenues (in millions)	\$50.3	\$53.4	\$40.2
Earnings (loss) per share	(\$7.17)*	(\$2.15)*	(\$0.40)*

52-Week range	\$1.58 – \$0.47	Fiscal year ends:	December
Shares outstanding a/o 11/14/24	23.3 million	Revenue/shares (ttm)	\$3.41
Approximate float	15.7 million	Price/Sales (ttm)	0.2X
Market Capitalization	\$12.6 million	Price/Sales (2025) E	NA
Tangible Book value/shr	\$1.17	Price/Earnings (ttm)	NMF
Price/Book	0.5X	Price/Earnings (2025) E	NA

* Excludes (\$25.99), (\$0.60), and (\$0.32) per share in 2022, 2023, and 2024 respectively, related to recognition of Deemed dividends

Cosmos Health Inc., headquartered in Chicago, Illinois is a diversified vertically integrated global health organization that manufactures and distributes medical grade nutritional and medicines. Cosmos owns a portfolio of proprietary pharmaceutical and nutraceutical brands (Sky Premium Life®, Mediterranean®, bio-bebe® and C-Sept®). Its CANA Laboratories subsidiary is licensed to manufacture pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union.


Key Investment Considerations:

Discontinuing coverage due to termination of services.


Please view our Disclosures on pages 2 – 4.

37 Main Street, Cold Spring Harbor, N.Y. 11724
(631) 757-1500

Price Chart



Taglich Brothers Current Ratings Distribution



75 % Buy | 25 % Hold

Investment Banking Services for Companies Covered in the Past 12 Months		
Rating	#	%
Buy	2	17
Hold		
Sell		
Not Rated		

Important Disclosures

As of the date of this report, we, our affiliates, any officer, director or stockholder, or any member of their families do not have a position in the stock of the company mentioned in this report. Taglich Brothers, Inc. does not currently have an Investment Banking relationship with the company mentioned in this report and was not a manager or co-manager of any offering for the company with in the last three years.

All research issued by Taglich Brothers, Inc. is based on public information. In February 2024, upon execution of the agreement and prior to any research services being provided, the company paid Taglich Brothers a monetary fee of \$3,000 representing payment for the first month of research coverage after publication. The second month after publication of the initial report, the company should have paid Taglich Brothers a monthly monetary fee of \$3,000 for the creation and dissemination of research reports for a minimum of twelve months (February 2025) after the date the initiation report was first published (February 2024).

General Disclosures

The information and statistical data contained herein have been obtained from sources, which we believe to be reliable but in no way are warranted by us as to accuracy or completeness. We do not undertake to advise you as to changes in figures or our views. This is not a solicitation of any order to buy or sell. Taglich Brothers, Inc. is fully disclosed with its clearing firm, Axos Clearing, LLC, is not a market maker and does not sell to or buy from customers on a principal basis. The above statement is the opinion of Taglich Brothers, Inc. and is not a guarantee that the target price for the stock will be met or that predicted business results for the company will occur. There may be instances when fundamental, technical and quantitative opinions contained in this report are not in concert. We, our affiliates, any officer, director or stockholder or any member of their families may from time to time purchase or sell any of the above-mentioned or related securities. Analysts and members of the Research Department are prohibited from buying or selling securities issued by the companies that Taglich Brothers, Inc. has a research relationship with, except if ownership of such securities was prior to the start of such relationship, then an Analyst or member of the Research Department may sell such securities after obtaining expressed written permission from Compliance.

Analyst Certification

I, Howard Halpern, the research analyst of this report, hereby certify that the views expressed in this report accurately reflect my personal views about the subject securities and issuers; and that no part of my compensation was, is, or will be directly or indirectly related to the specific recommendations or views contained in this report.

Public Companies mentioned in this report:

Meaning of Ratings

Buy – The growth prospects, degree of investment risk, and valuation make the stock attractive relative to the general market or comparable stocks.

Speculative Buy – Long-term prospects of the company are promising but investment risk is significantly higher than it is in our BUY-rated stocks. Risk-reward considerations justify purchase mainly by high risk-tolerant accounts. In the short run, the stock may be subject to high volatility and could continue to trade at a discount to its market.

Neutral – Based on our outlook the stock is adequately valued. If investment risks are within acceptable parameters, this equity could remain a holding if already owned.

Sell – Based on our outlook the stock is significantly overvalued. A weak company or sector outlook and a high degree of investment risk make it likely that the stock will underperform relative to the general market.

Discontinued – Research coverage discontinued due to the acquisition of the company, termination of research services (includes non-payment for such services), diminished investor interest, or departure of the analyst.

Some notable Risks within the Microcap Market

Stocks in the Microcap segment of the market have many risks that are not as prevalent in Large-cap, Blue Chips or even Small-cap stocks. Often it is these risks that cause Microcap stocks to trade at discounts to their peers. The most common of these risks is liquidity risk, which is typically caused by small trading floats and very low trading volume which can lead to large spreads and high volatility in stock price. In addition, Microcaps tend to have significant company-specific risks that contribute to lower valuations. Investors need to be aware of the higher probability of financial default and higher degree of financial distress inherent in the microcap segment of the market.

From time to time our analysts may choose to withhold or suspend a rating on a company. We continue to publish informational reports on such companies; however, they have no ratings or price targets. In general, we will not rate any company that has too much business or financial uncertainty for our analysts to form an investment conclusion, or that is currently in the process of being acquired.